Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Lapatinib plus capecitabine in treating HER2-positive advanced breast cancer: efficacy, safety, and biomarker results from Chinese patients.

Chinese journal of cancer - 1 May 2011

Xu Bing-He, Jiang Ze-Fei, Chua Daniel, Shao Zhi-Min, Luo Rong-Cheng, Wang Xiao-Jia, Liu Dong-Geng, Yeo Winnie, Yu Shi-Ying, Newstat Beth, Preston Alka, Martin Anne-Marie, Chi Hai-Dong, Wang Li

Abstract excerpt

Overexpression of human epidermal growth factor receptor-2 (HER2) in metastatic breast cancer (MBC) is associated with poor prognosis. This single-arm open-label trial (EGF109491; NCT00508274) was designed to confirm the efficacy and safety of lapatinib in combination with capecitabine in 52 heavily pretreated Chinese patients with HER2-positive MBC. The primary endpoint was clinical benefit rate (CBR). Secondary...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Capecitabine
Share to Deoxycytidine

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Exanthema

Share to Fluorouracil

Share to Lapatinib

Share to Quinazolines

Share to Receptor, ErbB-2

Share to Remission Induction

Source

Open in PubMed Open full text

Identifiers

PMID: 21527065
DOI: 10.5732/cjc.010.10507
PMCID: PMC4013397

Genes

TTR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Lapatinib plus capecitabine in treating HER2-positive advanced breast cancer: efficacy, safety, and biomarker results from Chinese patients.PMID 21527065Read ↗

The efficacy and safety of pyrotinib in treating HER2-positive metastatic breast cancer patients:A multi-center studySemantic proximity Read ↗

A randomized phase II trial of trastuzumab plus capecitabine versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer previously treated with trastuzumab and taxanes: WJOG6110B/ELTOP.Semantic proximity Read ↗

A phase 1 study of cetuximab and lapatinib in patients with advanced solid tumor malignancies.Semantic proximity Read ↗

The Cyclin D1 (CCND1) A870G polymorphism predicts clinical outcome to lapatinib and capecitabine in HER2-positive metastatic breast cancer.Semantic proximity Read ↗

A Phase II Biomarker-Embedded Study of Lapatinib plus Capecitabine as First-line Therapy in Patients with Advanced or Metastatic Gastric Cancer.Semantic proximity Read ↗

Efficacy and safety of Orelabrutinib-based regimens in diffuse large B-cell lymphoma: A single-center retrospective analysisSemantic proximity Read ↗

HLA-DQA1*02:01 is a major risk factor for lapatinib-induced hepatotoxicity in women with advanced breast cancer.Semantic proximity Read ↗

Tolerability of Eribulin and Correlation Between Polymorphisms and Neuropathy in an Unselected Population of Female Patients with Metastatic Breast Cancer: Results of The Multicenter, Single Arm, Phase IV PAINTER StudySemantic proximity Read ↗

Cost-effectiveness of Trastuzumab emtansine and Capecitabine plus lapatinib in adjuvant treatment of Human Epidermal Growth Factor Receptor 2– Positive Metastatic Breast Cancer in ChinaSemantic proximity Read ↗

The Prospective role of lapatinib as an adjuvant therapy in prevalent cancers: Insights from in silico analysis targeting EGFR and HER2Semantic proximity Read ↗

Differential sensitivity of ERBB2 kinase domain mutations towards lapatinib.Semantic proximity Read ↗

Pamiparib in patients with locally advanced or metastatic HER2-negative breast cancer with germline BRCA mutations: a phase II study.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.